KR102583365B1 - Micrococcus antarcticus strain and its use for improving skin conditions - Google Patents

Abstract

It relates to a novel Micrococcus antarcticus MC-1 strain, its lysate, culture medium, extract, composition containing the same, and their use for improving skin condition. According to one aspect, the new Micrococcus antarcticus strain has anti-skin aging, improvement of skin wrinkles, improvement of skin inflammation, improvement of atopy, and anti-itching effects, so it can be applied in various ways for skin improvement, prevention, or treatment. You can.

Description

Micrococcus antarcticus strain and its use for improving skin conditions {Micrococcus antarcticus strain and its use for improving skin conditions}

It relates to novel microorganisms, their disrupted liquid, culture medium, and extract liquid, and their use for improving skin condition.

The skin ecosystem provides various types of habitats for microorganisms, and a wide range of microorganisms live there. Human hosts have a symbiotic relationship with them, and they are known to have many positive effects on the host. The skin constitutes various types of habitats, including indentations and specialized crevices, and helps a wide range of microorganisms to grow. Basically, the skin forms a physical membrane and helps defend against potential hazards and toxic substances from the outside. The skin serves as a point of contact with the external environment and is also a collection site for various microorganisms (fungi, bacteria, viruses, and small larvae). Depending on the selection of physical and chemical functions, microorganisms adapt to specialized niches and establish habitats. Typically, the skin remains cool, acidic, and dry. Structurally, the epidermis forms the skin barrier and plays an important role in blocking the penetration of microorganisms and toxins and maintaining moisture. The uppermost layer of the epidermis is composed of the stratum corneum. The epidermis has a form called a 'brick and mortar structure'. The skin tissue goes through a continuous self-recovery process, and the scales (squames) that have completed the differentiation process constantly repeat the process of being shed from the skin tissue.

Probiotics are a general term for microorganisms that have beneficial effects on the human body. They refer to microorganisms that benefit our bodies. Most probiotics known to date are known as lactic acid bacteria. Probiotics have been reported to produce effective effects through various beneficial effects on the human body, but research on the relationship between skin flora and skin is insufficient.

Accordingly, there is a need to develop skin flora that can be useful for skin-related conditions.

KR 10-2273233 B1

One aspect is to provide novel Micrococcus antarcticus strains.

Another aspect is to provide a lysate, culture medium, or extract of the culture medium of the strain.

Another aspect is to provide a composition comprising the Micrococcus antarcticus strain, its lysate, culture medium, or extract of the culture medium.

Another aspect provides a method of preventing, ameliorating, or treating a condition in a subject comprising administering an effective amount of the composition described above to the subject in need thereof.

One aspect provides a strain of Micrococcus antarcticus .

The strain may be isolated. In this specification, the term “isolated” means something that does not exist in the natural world but can be artificially separated and used. The strain may be isolated from human skin. The strain may be isolated from human keratinocytes. The strain may be a strain isolated by inoculating human keratinocytes into R2A (Reasoner's 2A) medium (Becton Dickinson, Cockeysville, MD) and pure isolation and culturing of the cultured colonies.

The strain may be a strain belonging to the Micrococcus genus ( Micrococcus sp. ).

The strain contains 16S rRNA having a sequence identity of at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, or at least about 99.9% with SEQ ID NO: 1. It may be. The strain may contain 16S rRNA of SEQ ID NO: 1.

As used herein, the term “sequence identity” refers to the degree of identity of amino acid residues or bases between sequences after aligning both sequences to be as consistent as possible in a specific comparison region. Sequence identity can be confirmed according to methods known in the art. The percent sequence identity can be determined using known sequence comparison programs, examples of which include BLASTN (NCBI), CLC Main Workbench (CLC bio), MegAlignTM (DNASTAR Inc), etc.

The Micrococcus antarcticus strain may be a strain deposited under the deposit number KCCM12995P. The strain deposited with the above deposit number may be Micrococcus antarcticus MC-1 strain.

The strain may have an effect of improving skin condition. For example, the skin condition improvement may be one or more of preventing skin aging, improving skin wrinkles, improving skin inflammation, improving atopy, and suppressing itching.

Another aspect provides a lysate, culture fluid, or extract of the culture fluid of the strain.

Specific details of the strain are as described above.

As used herein, the term “lysate” may be used interchangeably with “lysate” and may refer to a product obtained by breaking the cell wall of a strain by chemical or physical force. The lysate may include the lysate itself, its concentrate, or its freeze-dried product.

As used herein, the term “culture medium” may be used interchangeably with “culture supernatant,” “conditioned culture medium,” or “conditioned medium,” and provides nutrients to allow Micrococcus antarcticus strains to grow and survive in vitro. It may refer to the entire medium containing the strain, its metabolites, extra nutrients, etc. obtained by culturing the strain for a certain period of time in a medium capable of supplying. Additionally, the culture medium may refer to a culture medium obtained by removing the bacterial cells from the bacterial culture medium obtained by culturing the strain. On the other hand, the liquid from which the bacteria have been removed from the culture medium is also called "supernatant", and the culture medium is left alone for a certain period of time and only the liquid in the upper layer excluding the part that has settled in the lower layer is taken, the bacteria are removed through filtration, or the culture medium is centrifuged to remove the lower layer. It can be obtained by removing the precipitation and taking only the upper liquid. The "bacteria" refers to the strain itself of the present invention, and includes the strain itself isolated and selected from a sample, etc., or a strain isolated from the culture medium by culturing the strain. The bacterial cells can be obtained by centrifuging the culture medium and taking the part that sinks to the lower layer. Alternatively, since they sink to the lower layer of the culture medium by gravity, they can be obtained by leaving them still for a certain period of time and then removing the upper liquid.

The culture medium may include the culture medium itself, a concentrate or freeze-dried product obtained by cultivating the strain, or a culture supernatant obtained by removing the strain from the culture medium, a concentrate or a freeze-dried product thereof.

Culture media and culture conditions for culturing the Micrococcus antarcticus strain can be appropriately selected or modified by those skilled in the art. For example, the culture medium is obtained by culturing in a medium (e.g., R2A medium, RCM medium, or TSA medium) at any temperature above 10°C or below 40°C for a certain period of time, for example, 4 to 50 hours. It may be.

As used herein, the term "culture extract" refers to an extract from the culture medium or its concentrate, and may include the extract, a diluted or concentrated liquid of the extract, a dried product obtained by drying the extract, or a crude or purified product thereof, or a fraction thereof. You can.

The strain, its lysate, culture medium, or extract of the culture medium may be biologically pure. The strain may be obtained by pure culture.

Another aspect provides the use of a Micrococcus antarcticus strain, a lysate, a culture, or an extract of the culture of the strain. In detail, a composition comprising a Micrococcus antarcticus strain, its lysate, culture medium, or extract of the culture medium is provided.

In the above use or composition, the Micrococcus antarcticus strain may be the Micrococcus antarcticus strain according to the above aspect. In one embodiment, the strain may be isolated from human skin. In other embodiments, the strain has at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, or at least about 99.9% sequence identity with SEQ ID NO: 1. It may contain 16S rRNA. In another embodiment, the strain may contain 16S rRNA of SEQ ID NO: 1. In another embodiment, the strain may be a strain deposited under deposit number KCCM12995P.

Uses of the strain may include improving skin condition, improving skin beauty, and preventing, improving, or treating skin diseases.

The improvement of skin condition or skin beauty may be one or more of preventing skin aging, improving skin wrinkles, improving skin inflammation, improving atopy, and suppressing itching.

The strain increases COL1A1 expression; reduce MMP-1 expression; It may be reducing IL-6 expression.

As used herein, the term "skin aging" refers to both tangible and intangible changes that occur in the skin as one ages, such as thinning of the epidermis, decrease in the number of cells or blood vessels in the dermis, decrease in DNA damage repair ability, and cell replacement. Reduced cycle time, reduced wound healing ability, reduced skin barrier function, reduced epidermal moisture retention function, reduced vitamin D production, reduced physical damage defense function, reduced chemical removal ability, reduced immune response, reduced sensory function, reduced body temperature regulation, etc. says

The skin aging may be caused by extrinsic factors or endogenous factors. The exogenous factors refer to various external factors, such as ultraviolet rays (light), and the endogenous factors are also referred to as chronological factors and mainly refer to factors that occur due to the passage of time. In other words, the skin aging is not only a premature aging phenomenon induced by external stimuli such as ultraviolet rays, pollution, cigarette smoke, chemicals, etc., but also a natural aging phenomenon that occurs as the proliferation of skin cells decreases with age. It is a concept that includes wrinkles, loss of elasticity, skin sagging, and dryness. In addition, wrinkles include stimulation caused by changes in internal and external factors that change the components that make up skin tissue, causing wrinkles.

The aging may be photoaging. The term “photoaging” is a phenomenon caused by external environmental factors, the most representative factor being ultraviolet rays. Ultraviolet rays cause damage to biological components such as activation of proteolytic enzymes, chain cleavage of matrix proteins, and abnormal cross-linking, and repetition of this mechanism causes skin aging that is evident in appearance.

As used herein, the term “wrinkle” refers to a state in which the skin loses its elasticity and becomes loose, for example, the skin may be folded. The term “prevention or improvement of skin wrinkles” may refer to any action that prevents or improves wrinkles by suppressing the expression of factors related to wrinkles, or increases the total amount of collagen.

As used herein, the term "improvement of inflammation" may be used interchangeably with "inhibition of inflammation" and "anti-inflammation" and may refer to any action that alleviates the immune response and suppresses NO production.

As used herein, the term “skin disease” may be a disease or skin inflammation caused by damage to the skin barrier function. As used herein, the term “prevention” includes suppressing the occurrence of a disease. As used herein, the term “treatment” includes inhibiting, alleviating, or eliminating the development of a disease.

The skin inflammatory disease may be any one selected from the group consisting of dermatitis, atopic dermatitis, pruritus (itching), eczematous skin disease, dry eczema, erythema, urticaria, psoriasis, drug rash, and acne.

The composition according to one aspect includes the Micrococcus antarcticus strain, its lysate, culture medium, or extract of the culture medium, thereby increasing the expression of COL1A1 or reducing the expression of MMP-1, thereby preventing skin aging and improving skin wrinkles. It can show an effect.

The composition according to one aspect includes the Micrococcus antarcticus strain, its lysate, culture medium, or extract of the culture medium, thereby reducing the expression of inflammatory cytokines (e.g., IL-6), improving skin inflammation, or reducing skin inflammation. It can be effective in preventing, improving, or treating skin diseases such as skin diseases, atopy, and itching.

In another embodiment, the strain can be used together with another strain that has an effect to improve skin condition, for example, a strain belonging to the Micrococcus genus, to exhibit a synergistic effect.

The composition is 0.001% to 80% by weight, for example, 0.01% to 60% by weight, 0.01% to 40% by weight, 0.01% to 30% by weight, 0.01% to 20% by weight, based on the total weight of the composition. %, 0.01% to 10% by weight, 0.01% to 5% by weight, 0.05% to 60% by weight, 0.05% to 40% by weight, 0.05% to 30% by weight, 0.05% to 20% by weight, 0.05% to 10% by weight, 0.05% to 5% by weight, 0.1% to 60% by weight, 0.1% to 40% by weight, 0.1% to 30% by weight, 0.1% to 20% by weight, 0.1% by weight It may contain % to 10% by weight, or 0.1% to 5% by weight of the strain, its lysate, culture medium, or extract of the culture medium.

As used herein, the term "included as an active ingredient" means that the strain of the present specification, its lysate, culture medium, or extract of the culture medium is added to the extent that it can exhibit the above-mentioned effects, and provides drug delivery and stabilization, etc. This means that it is formulated into various forms by adding various ingredients as sub-ingredients.

The composition may be in a liquid state or a dry state. In one embodiment, the composition may be in dry powder form.

The drying method for preparing the composition in a dry state may be a method generally used in the art and is not particularly limited. Non-limiting examples of the drying method include air drying method, natural drying method, spray drying method, freeze drying method, etc. These methods can be used alone or at least two methods can be used together.

The composition may contain an effective amount of additives sufficient to reduce deterioration of the strain, its lysate, culture medium, or extract of the culture medium. The additive may be, for example, a binder, but is not limited thereto.

The composition may further include a cosmetically, pharmaceutically, or foodologically acceptable carrier. The composition can be formulated with a carrier and provided as cosmetics, drugs, food additives, etc.

The composition may be a cosmetic composition.

In addition to the active ingredients disclosed in this specification, the cosmetic composition may further include ingredients commonly used in cosmetic compositions, functional additives, etc., such as antioxidants, stabilizers, solubilizers, surfactants, dispersants, emulsifiers, and preservatives. , conventional auxiliaries such as vitamins, pigments, fragrances, etc., and carriers.

The cosmetic composition is not particularly limited to a specific formulation, and the formulation may be appropriately selected depending on the purpose. The cosmetic composition may have, for example, a solubilized formulation, an emulsified formulation, or a dispersed formulation. The cosmetic composition may have, for example, an softening lotion, a nourishing lotion, a massage cream, a nourishing cream, an essence, a pack, a gel, an ampoule, or a skin-adhesive cosmetic formulation.

The composition may be a composition for external skin application.

In this specification, the external skin agent may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal delivery patch, drug-containing bandage, lotion, or a combination thereof. The skin external preparations include ingredients commonly used in external skin preparations such as cosmetics and medicines, such as aqueous ingredients, oil-based ingredients, powder ingredients, alcohols, moisturizers, thickeners, ultraviolet absorbers, whitening agents, preservatives, antioxidants, surfactants, and fragrances. , colorants, various skin nutrients, or a combination thereof may be appropriately mixed according to need. The skin external preparations include metal sequestrants such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid; Drugs such as caffeine, tannin, bellapamil, licorice extract, glablidin, hot water extract of calin fruit, various herbal medicines, tocopherol acetate, glythylitic acid, tranexamic acid and its derivatives or salts; Vitamin C, magnesium ascorbyl phosphate, ascorbate glucoside, arbutin, kojic acid; Sugars such as glucose, fructose, and trehalose can also be appropriately mixed.

The composition may be a pharmaceutical composition.

The pharmaceutical composition may additionally include a pharmaceutically acceptable diluent or carrier. The diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, mannitol, or a combination thereof. The carrier may be an excipient, disintegrant, binder, lubricant, or a combination thereof. The excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof. The disintegrant may be calcium carboxymethylcellulose, sodium starch glycolate, calcium monohydrogen phosphate anhydride, or a combination thereof. The binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, or a combination thereof. The lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.

The pharmaceutical composition may be formulated as an oral or parenteral dosage form. Oral dosage forms may be granules, powders, solutions, tablets, capsules, dry syrup, etc. Parenteral dosage forms may be injections, ointments, etc.

The composition may be a health functional food composition. In this case, it can be formulated in the form of a typical health functional food known in the art.

The health functional food composition may use the strain, its lysate, culture medium, or extract of the culture medium alone, or may be used together with other foods or food ingredients, and may be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment). There are no particular restrictions on the types of health functional foods. Among the types of health functional foods, beverage compositions may contain various flavoring agents or natural carbohydrates as additional ingredients like ordinary beverages. The natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; and polysaccharides such as dextrins and cyclodextrins; Sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, natural sweeteners such as thaumatin and stevia extract or synthetic sweeteners such as saccharin and aspartame can be used. The food composition is also used in nutritional supplements, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonated beverages. It may contain a carbonating agent, or a combination thereof. The food composition may also contain pulp for the production of natural fruit juice, fruit juice beverage, vegetable beverage, or a combination thereof.

Another aspect provides a method of preventing, ameliorating, or treating a condition in a subject comprising administering an effective amount of the composition described above to the subject in need thereof.

The subject's condition may be a skin-related condition, or a condition related to skin inflammation.

As used herein, the terms “administering,” “introducing,” and “implanting” are used interchangeably and refer to an individual by a method or route that results in at least partial localization of the composition according to one embodiment to the desired site. It may refer to the arrangement of the composition according to one embodiment into the inner space.

Administration can be done by methods known in the art. Administration may be administered directly to the subject by any means, such as, for example, intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal or subcutaneous administration. You can. The administration may be administered systemically or locally.

The subject may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat, or cat. The subject may be an individual in need of skin improvement, for example, an individual in need of anti-aging skin, improvement of skin wrinkles, improvement of skin inflammation, improvement of atopy, or anti-itch effect.

The administration of the composition according to one embodiment is 0.1 mg to 1,000 mg, for example, 0.1 mg to 500 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 1 mg to 1 mg per day. 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg , 5 mg to 50 mg , 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg to 100 mg, 10 mg to 50 mg, or 10 mg to 25 mg. However, the dosage may be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, gender, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity, and those skilled in the art will Taking these factors into consideration, the dosage can be adjusted appropriately. The frequency of administration can be once a day or two or more times within the range of clinically acceptable side effects, and can be administered at one or two or more locations, daily or at intervals of 2 to 5 days. The number of days of administration can be from 1 to 30 days per treatment. If necessary, the same treatment can be repeated after an appropriate period. For animals other than humans, the dosage per kg is the same as for humans, or the above dosage is converted into, for example, the volume ratio (e.g., average value) of the organs (heart, etc.) between the target animal and human. One dose can be administered.

According to one aspect, the new Micrococcus antarcticus strain has anti-skin aging, improvement of skin wrinkles, improvement of skin inflammation, improvement of atopy, and anti-itching effects, so it can be applied in various ways for skin improvement, prevention, or treatment. You can.

Figure 1 shows the relative expression level of COL1A1 in fibroblasts.
Figure 2 shows the relative expression level of MMP-1 in fibroblasts.
Figure 3 shows the relative expression level of IL-6 in keratinocytes.

Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.

Example 1. Isolation and identification of strains

Micrococcus antarcticus strains were isolated and identified from the skin of healthy women.

Specifically, a sample obtained by washing the skin of a healthy woman with sterile distilled water, that is, human epidermal keratinocytes, was inoculated into R2A (Reasoner's 2A) medium (Becton Dickinson, Cockeysville, MD). After inoculation, 100 colonies formed after culturing in an incubator at 28°C for 48 hours were isolated and cultured in pure form, and re-cultured in an incubator at 28°C for 48 hours.

The 16S rRNA gene sequence of the colonies after completion of culture was identified. Specifically, PCR was performed using primers designed to amplify only bacteria. PCR amplification was performed in 30 cycles of 95°C for 1 minute, 55°C for 1 minute, and 75°C for 1 minute and 30 seconds, and was finally treated at 72°C for 8 minutes and stored at 4°C. After the PCR reaction was completed, the DNA sequences of the isolated and cultured species were determined using ABI-3730XL (ABI, USA).

When the nucleotide sequence of the 16S rRNA region determined among the isolated and cultured microbial colonies was compared and analyzed with other strains registered using the BLAST program provided on the website of the National Center for Biotechnology Information (NCBI), homology was found to be 99. % or less of the new microorganism Micrococcus antarcticus ( Micrococcus antarcticus ) strain (hereinafter referred to as “MC-1”) was selected. The selected MC-1 strain was deposited at the Korea Center for Microbial Conservation (KCCM) on May 28, 2021, and was given the deposit number KCCM12995P. MC-1 strain has the 16S rRNA sequence of SEQ ID NO: 1 (complementary DNA).

Experimental Example 1. Analysis of anti-aging and anti-wrinkle activity - Confirmation of increased COL1A1 expression and decreased MMP-1 expression

To analyze the effect of the culture medium of the MC-1 strain isolated in Example 1 on factors related to skin aging and wrinkle formation in aging skin caused by ultraviolet (UV) irradiation, COL1A1 (Collagen, type I, alpha 1) And the expression of MMP-1 (Matrix metalloproteinase-1) was confirmed.

Specifically, the human fibroblast cell line (Human dermal fibroblast, Hs68) was distributed at 3.5x10 ⁵ in a 6-well plate and then cultured in an incubator at 37°C and 5% CO ₂ for 24 hours. Afterwards, the medium was removed, DPBS (Dulbecco's phosphate-buffered saline) was added, and UVB of 12 mJ/cm ² was irradiated or not. Immediately after UVB irradiation, DPBS was removed and the medium was changed to FBS-free medium, and then treated with 1% (w/w) of the culture medium of the MC-1 strain and further cultured for 24 hours. As a negative control group, a group untreated with ultraviolet rays and strain culture was used.

Afterwards, RNA was isolated from the cells of each sample using Trizol (RNA iso, DAKARA, Japan), RNA was quantified at 260 nm using a nanodrop, and 2 ㎍ of RNA was used in an amplifier. cDNA was synthesized (C1000 Thermal Cycler, Bio-Rad, USA). Using the synthesized cDNA as a template, CyberGreen (SYBR Green supermix, Applied Biosystems, USA) was added to the target genes COL1A1 and MMP-1 along with primers and cDNA, and then run on a real-time PCR machine (Step One Plus, Applied). Real-time polymerase chain reaction was performed by Biosystems, USA). The expression level of the gene was finally analyzed through correction for the β-actin gene, and the results are shown in Figures 1 and 2.

As shown in Figure 1, the MC-1 strain was confirmed to significantly increase the expression of COL1A1, which was reduced by ultraviolet rays.

As shown in Figure 2, the MC-1 strain was confirmed to significantly reduce the expression of MMP-1 increased by ultraviolet rays.

These results mean that the MC-1 strain is effective in preventing skin aging (eg, photoaging) and improving skin wrinkles.

Experimental Example 2. Anti-inflammatory, anti-atopic and itching inhibition activity analysis - confirmation of decreased IL-6 expression

In order to analyze whether the culture medium of the MC-1 strain isolated in Example 1 had anti-inflammatory, anti-atopic and anti-itching activities, the expression of the inflammatory cytokine IL-6 was confirmed.

Specifically, HaCaT cells, a human keratinocyte cell line, were cultured in DMEM medium (Dulbecco's modified Eagle's Medium, Gibco 1210-0038) containing 10% fetal bovin serum, and all cultures were performed at 37°C for 5 days. It was performed in a % CO ₂ incubator. The medium was changed every 3 to 4 days, and when the cells proliferated excessively, they were subcultured. Afterwards, the cells were distributed at 5x10 ⁵ /well and after 24 hours of culture, they were washed with phosphate buffered saline solution (PBS). Cells were dispensed into each well containing DMEM medium without FBS, and 10 μg/ml of Poly I:C and 10 ng/ml of IL-4 were added to induce inflammation in the keratinocyte cell line. Next, the culture medium of the above strain was treated at a concentration of 1% (w/w) and further cultured for 4 hours. As a positive control, dexamethasone 1 μM was used. The expression level of IL-6 was analyzed in the same manner as in Experimental Example 1, except that primers for IL-6 were used. The expression level of the gene was finally analyzed through correction for the β-actin gene, and the results are shown in Figure 3.

As shown in Figure 3, the MC-1 strain was confirmed to significantly reduce the expression of IL-6, an inflammatory cytokine, compared to the untreated control group.

These results mean that the MC-1 strain can be usefully used to prevent, improve, or treat skin inflammatory diseases, atopy, and itching.

In summary, Micrococcus antarcticus MC-1 strain increases COL1A1 expression and decreases MMP-1 expression; It was confirmed that IL-6 expression was reduced. Therefore, it was found that Micrococcus antarcticus MC-1 strain has the effect of preventing skin aging, improving skin wrinkles, improving skin inflammation, improving atopy, and suppressing skin itching.

The above description is merely an illustrative explanation of the technical idea of the present invention, and various modifications and variations will be possible to those skilled in the art without departing from the essential characteristics of the present invention.

Korea Microbiological Conservation Center (Overseas) KCCM12995P 20210528

SEQUENCE LISTING <110> Cosmax, INC. <120> Micrococcus antarcticus strain and its use for improving skin conditions <130> PN139629 <160> 1 <170> PatentIn version 3.2 <210> 1 <211> 1322 <212> DNA <213> Micrococcus antarcticus <400> 1 aggatgaacg ctggcggcgt gcttaacaca tgcaagtcga acgatgaagc ccagcttgct 60 gggtggatta gtggcgaacg ggtgagtaac acgtgagtaa cctgcccttg actctaggat 120 aagcccggga aactgggtct aatactggat aggaacgtct accgcatggt ggatgttgga 180 aagaatttcg gtcatggatg gactcgcggc ctatcagctt gttggtgagg taatggctca 240 ccaaggcgac gacgggtagc cggcctgaga gggtgaccgg ccacactggg actgagacac 300 ggcccagact cctacgggag gcagcagtgg ggaatattgc acaatgggcg aaagcctgat 360 gcagcgacgc cgcgtgaggg atgacggcct tcgggttgta aacctctttc agtagggaag 420 aagcgaaagt gacggtacct gcagaagaag caccggctaa ctacgtgcca gcagccgcgg 480 taatacgtag ggtgcgagcg ttatccggaa ttattgggcg taaagagctc gtaggcggtt 540 tgtcgcgtct gtcgtgaaag tccggggctt aaccccggat ctgcggtggg tacgggcaga 600 ctagagtgca gtaggggaga ctggaattcc tggtgtagcg gtggaatgcg cagatatcag 660 gaggaacacc gatggcgaag gcaggtctct gggctgtaac tgacgctgag gagcgaaagc 720 atggggagcg aacaggatta gataccctgg tagtccatgc cgtaaacgtt gggcactagg 780 tgtggggaac attccacgtt ttccgcgccg cagctaacgc attaagtgcc ccgcctgggg 840 agtacggccg caaggctaaa actcaaagga attgacgggg gcccgcacaa gcggcggagc 900 atgcggatta attcgatgca acgcgaagaa ccttaaccaag gcttgacatg ttctcgatcg 960 ccgtagagat acggtttccc ctttggggcg ggttcacagg tggtgcatgg ttgtcgtcag 1020 ctcgtgtcgt gagatgttgg gttaagtccc gcaacgagcg caaccctcgt tccatgttgc 1080 cagcacttcg ggtggggact catgggagac tgccggggtc aactcggagg aaggtgggga 1140 cgacgtcaaa tcatcatgcc ccttatgtct tgggcttcac gcatgctaca atggccggta 1200 caatgggttg cgatactgtg aggtggagct aatcccaaaa agccggtctc agttcggatt 1260 ggggtctgca actcgacccc atgaagtcgg agtcgctagt aatcgcagat cagcaacgct 1320 gc 1322

Claims (9)

As Micrococcus antarcticus MC-1 strain deposited with deposit number KCCM12995P,
The strain increases COL1A1 expression; reduce MMP-1 expression; A strain that reduces IL-6 expression. The strain according to claim 1, comprising 16S rRNA of SEQ ID NO: 1. Culture medium of the strain of claim 1. A cosmetic composition for improving skin wrinkles comprising the strain of claim 1, its lysate, or culture medium. The method of claim 4, wherein COL1A1 expression is increased; A cosmetic composition that reduces MMP-1 expression. A cosmetic composition for improving skin inflammation, improving atopy, or suppressing itching, comprising the strain of claim 1, its lysate, or culture medium,
A cosmetic composition in which the improvement of skin inflammation, atopy, or itching is achieved by reducing IL-6 expression. A pharmaceutical composition for preventing or treating inflammatory skin diseases comprising the strain of claim 1, its lysate, or culture medium as an active ingredient,
A pharmaceutical composition for preventing or treating the skin inflammatory disease by reducing IL-6 expression. A health functional food composition for improving skin wrinkles comprising the strain of claim 1, its lysate, or culture medium. A health functional food composition for improving skin inflammation, improving atopy, or suppressing itching, comprising the strain of claim 1, its lysate, or culture medium,
A health functional food composition in which the improvement of skin inflammation, atopy, or itching is achieved by reducing IL-6 expression.